Taltz Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The taltz market research report is one of a series of new reports that provides taltz market statistics, including taltz industry global market size, regional shares, competitors with a taltz market share, detailed taltz market segments, market trends and opportunities, and any further data you may need to thrive in the taltz industry. This taltz market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to the increasing prevalence of autoimmune diseases, rising healthcare expenditure globally, government initiatives for chronic disease management, expansion in emerging markets, growing adoption of personalized medicine. Major trends in the forecast period include a shift toward self-administration biologics, technological innovations in drug formulation, strategic collaborations and licensing agreements, advancements in biologic drug delivery, growth in biosimilar competition.

The increasing prevalence of autoimmune diseases is expected to drive growth in the taltz market. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells and tissues, causing inflammation and damage. The rise in autoimmune diseases is influenced by factors such as genetic predisposition, environmental triggers, lifestyle changes, and advancements in diagnostic techniques that have improved awareness and identification. Taltz is used to treat these diseases by targeting and inhibiting specific inflammatory pathways, particularly interleukin-17A, helping to reduce inflammation and alleviate symptoms associated with conditions such as psoriasis and psoriatic arthritis. For example, in August 2022, a systematic review published by the National Library of Medicine found that in 2022, there were 928 cases of autoimmune diseases linked to COVID-19 vaccination, with 81.5% being new-onset cases. The growing prevalence of autoimmune disorders will contribute to the expansion of the taltz market.

Rising healthcare spending is another factor expected to drive the taltz market in the coming years. Healthcare spending refers to the total amount spent on medical services, treatments, hospital care, pharmaceuticals, and other health-related services. This increase in spending is due to factors such as an aging population, the rise of chronic diseases, and higher demand for healthcare services. The growth in healthcare expenditure benefits taltz by increasing access to advanced biologic therapies, improving diagnostic rates, and enhancing patient adherence through insurance coverage and support programs. For instance, in May 2024, the Office for National Statistics reported that healthcare spending in the UK increased by 5.6% between 2022 and 2023, compared to just 0.9% growth in 2022. As a result, the rising healthcare expenditure will support the growth of the taltz market.

A key trend in the taltz market is the focus on obtaining regulatory approvals to gain a competitive edge in the industry. Regulatory approval involves assessing and authorizing new drugs to ensure their safety, efficacy, and quality based on clinical data. For instance, Eli Lilly and Company launched a new citrate-free version of Taltz (ixekizumab) in 2022. This formulation, which received approval from the U.S. Food and Drug Administration (FDA) in May 2022, is designed to significantly reduce injection site pain, with clinical data showing an 86% reduction in pain compared to the original version. Taltz is approved for adults and children aged six and older with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is also approved for adults with active psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis that show signs of inflammation.

The key company operating in the taltz market is Eli Lilly and Company.

North America was the largest region in the taltz market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in taltz report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the taltz market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Taltz (ixekizumab) is a prescription biologic medication primarily used to treat autoimmune conditions, including moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. As a monoclonal antibody, it targets interleukin-17A (IL-17A), a protein involved in inflammatory processes, helping to alleviate symptoms such as joint pain, skin lesions, and stiffness.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main indications for Taltz include psoriasis, psoriatic arthritis, and ankylosing spondylitis. Psoriasis is a chronic skin condition where the immune system accelerates the growth of skin cells, causing red, flaky, and inflamed patches, often on areas such as the elbows, knees, and scalp. Taltz can be administered via subcutaneous injection or intravenous infusion and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It is used by both pediatric and adult patients.

The taltz market consists of sales of injectables and immunomodulators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.